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Immunohistochemical Detection of Survivin in Canine Lymphoma
Summary
Survivin is a member of the family of proteins known as 'inhibitors of apoptosis proteins'.
Survivin has a role in cellular decisions concerning division and survival and is frequently 
Introduction
Apoptosis is a phylogenetically conserved mechanism of cell death with roles in development and tissue homeostasis (Salvesen and Duckett, 2002) . In mammals, it is executed through activation of different caspases, which are present in the cell cytoplasm as inactive proenzymes. Activation of these molecules can be triggered either by external stimuli, which activate the extrinsic apoptotic pathway, or by diverse conditions collectively termed 'cellular stress', which activate the intrinsic pathway.
Following stress stimuli, cytochrome c is released from the mitochondrial intermembrane space into the cell cytoplasm, where it participates in the assembly of the apoptosome and subsequent activation of the initiator caspase-9. This enzyme cleaves and activates downstream caspases that target further cellular substrates for cleavage, eventually resulting in cell death (Gerl and Vaux, 2005) .
Inhibitors of apoptosis proteins (IAPs) are a family of proteins that interfere with the activation of caspases by various mechanisms (Salvesen and Duckett, 2002) . All members of the family possess at least one 'baculovirus inhibitor of apoptosis repeat', a specific domain that, at least in some of its versions, has been shown to bind and/or inactivate caspases. Increased expression of various IAPs has been reported in several types of cancer and is thought to contribute to the phenomenon of resistance to apoptosis that is often a feature of the neoplastic process. Survivin is a member of the IAP family with well known functions in the regulation of cell division. In contrast, its antiapoptotic function has long been debated and, only recently, relevant mechanisms have been unveiled in tumour cells (Altieri, 2008) . In order to inhibit apoptosis, survivin must localize to the cytosol and its negative regulatory effect on caspase function appears to be indirect (Stauber et al., 2007; Altieri, 2008) . Overexpression of survivin has been 8 reported in a wide range of human cancers, and, similarly to other IAPs, it has been shown to negatively influence outcome in many different types of cancer (Stauber et al., 2007) . Based mostly on early data from man, it is frequently claimed that survivin is widely expressed during embryonic development, but is not expressed or only weakly expressed in normal adult tissues (Ambrosini et al., 1997; Andersen et al., 2007; Altieri, 2008) . Some authors concede that survivin is expressed to some extent in adult tissues with a high cell turnover including testis, intestinal epithelium and bone marrow (Kobayashi et al., 1999) . Evidence that the role of survivin is not restricted to developing tissues is emerging, with several reports of its expression in normal adult tissues (Fukuda and Pelus, 2006; Lechler et al., 2007) .
Canine survivin is 91.5% homologous to its human counterpart at the amino acid level (Uchide et al., 2005) . Immunohistochemical studies have described expression of this protein in canine mast cell tumours (Scase et al., 2006) , haemangiomas and haemangiosarcomas (Murakami et al., 2008) , transitional cell carcinomas of the urinary bladder (Velando Rankin et al., 2008) and lymphomas (Rebhun et al., 2008) . The prognostic significance of this expression remains undetermined. It has been suggested that survivin might be expressed by all canine lymphomas and a negative prognostic significance has been attributed to high expression of survivin in B-cell neoplasms (Rebhun et al., 2008) . Survivin mRNA has been detected by reverse transcriptase polymerase chain reaction (RT-PCR) in the tissue of normal adult dogs including heart, lung, liver, stomach, duodenum, colon, spleen, kidney and testis, as well as in various tumour tissues (Uchide et al., 2005) . Immunohistochemical studies to confirm expression of survivin protein have not been performed.
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The aim of the present study was to establish a reliable method for immunohistochemical detection of survivin and to apply this methodology to a detailed analysis of expression of survivin protein in normal canine tissues and samples of canine lymphoma.
Materials and Methods
Primary Antibodies for Immunohistochemistry
Two commercially available antibodies raised against full-length human survivin were compared in immunohistochemistry (IHC). The first was a polyclonal, affinity purified antibody (survivin-astrocyte marker NB 500-201, Lot Q2; Novus Biologicals Inc., Littleton, Colorado) hereafter described as pSurv in this study. The second was a monoclonal antibody (survivin D8: sc-17779, StC Biotechnology Inc., Santa Cruz, California), referred to as mSurv in this study. The specific epitope recognized by the monoclonal antibody is unknown. Lymphomas were immunophenotyped by application of polyclonal anti-human pan T-cell (CD3) antibody (Dako Cytomation, Zug, Switzerland) and a monoclonal anti-human pan B-cell (CD79a) antibody (Dako Cytomation).
Cloning and Expression of Canine Survivin
Isolation of total RNA from Madin Darby Canine Kidney (MDCK) cells was performed with the RNeasy Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer's protocols and as described previously (Keller et al., 2007b 
Western Blotting
Following protein induction, bacterial cultures (1 ml) were centrifuged and the pellets were resuspended in 200 µl of 2x sodium dodecyl sulphate (SDS) buffer containing 10% β-mercaptoethanol. Samples were incubated at 95°C for 10 min, centrifuged for 5 min and 2 µl of bacterial lysates were loaded onto 12% SDS polyacrylamide gels and separated by gel electrophoresis (SDS-PAGE). After transferring the proteins to a nitrocellulose membrane by means of a semi-dry blotting system (Biometra, Goettingen, Germany), non-specific antibody binding sites were blocked by incubation of the membrane for 1h at room temperature in Tris-buffered saline containing Tween 20 0.05% (TBST) and bovine serum albumin (BSA) 3%. The membrane was washed three times for 15 sec and twice for 10 min in TBST and then incubated for 1 h at room temperature with pSurv (1 µg/ml in BSA 1 %) or mSurv (2 µg/ml in BSA 1%). Following this initial incubation, the membranes were washed again with TBST as described above and incubated with secondary anti-mouse IgG conjugated to horseradish peroxidase (HRP; Geno Technologies, St Louis, Missouri) or anti-rabbit IgG conjugated to HRP (Jackson, ImmunoResearch, Soham, UK) diluted 1 in 10,000 for 1 h at room temperature in BSA 1%. As a control for this analysis, the presence of GST-tagged proteins was detected using mouse anti-GST antibody (0.1 µg/ml) conjugated to HRP (Amersham Biosciences, Otelfingen, Switzerland). Signals were visualized following incubation with a LumiGlo TM substrate (KPL, Maryland) and autoradiography.
Keratinocyte Cultures
Methods for culture, fixation and embedding of normal and neoplastic canine keratinocytes have been described previously (Keller et al., 2007b) . Cells used included a normal canine keratinocyte line and a squamous cell carcinoma line (Crameri et al., 1997; Keller et al., 2007b) .
(GenBank Accession number: DQ225116), cIAP1 (DQ223014), cIAP2 (EF102104), Smac/DIABLO (EF088670), Omi/HtrA2 (DQ138643) and GST alone, in addition to control E. coli MG1655 wild-type cells were centrifuged at 4,000 g for 10 min at 4°C and the pellets were resuspended in 4% neutral buffered formaldehyd and incubated for 24 h at room temperature. The cultures were subsequently centrifuged at 4,000 g for 10 min
at room temperature. The resulting pellets were resuspended in 1.5 ml of 5% BSA in PBS plus 2 drops of hemalum in an Eppendorf tube before a final centrifugation at 4,000 g at room temperature for 10 min. The pellets were embedded in paraffin wax with the Cytoblock system (Thermo Shandon, Pittsburgh, Pennsylvania).
Tissue Array Construction
Tissue arrays were constructed from archival samples by means of a manual tissue array production apparatus (Beecher Instruments, Sun Prairie, USA). To minimize variation, all normal tissue and lymphoma samples used to assemble arrays were derived from patients that had been admitted to the Faculty clinic and all tissues had been fixed in house. The majority of the specimens derived from biopsies. The first array was composed of a broad spectrum of normal fetal and adult canine tissues (free of microscopical lesions) that had been fixed in 4% buffered formaldehyd for 24 to 48 h and embedded in paraffin wax. Fetal tissues included placenta, kidney, liver, pancreas, lung, intestine, skeletal muscle, heart muscle and brain. Adult tissues included placenta, kidney, liver, pancreas, spleen, lung, intestine, heart muscle, skeletal muscle, brain, testis and lymph node. The array was constructed by collecting two cores of 1.2 mm 13 diameter (fetal tissues) or 0.6 mm diameter (adult tissues) from representative areas of each specimen that were transferred to paraffin wax recipient blocks (Micro-Cut Paraffin, Polysciences Inc., Warrington, USA). Samples for each organ originated from two to three different individuals. A further series of arrays was constructed using 95 samples of canine lymphoma (Keller et al., 2007a) . Four cores of 0.6 mm diameter were collected from representative areas of each specimen. Before sectioning, the blocks were immersed in water, kept at -20°C for 15 min, cut into sections of 1.5 µm and transferred to positively charged glass slides (Erie Scientific Company, Portsmouth, New Hampshire).
Survivin Immunohistochemistry
An optimized immunohistochemical procedure for detection of canine survivin was developed by testing a series of different antigen retrieval methods, primary antibody dilutions and incubation conditions (Keller et al., 2007b) . The optimized conditions are described forthwith. Antigen retrieval was carried out for both anti-survivin antibodies by boiling the slides in Tris/ethylene diaminetetraacetic acid (EDTA) buffer pH 9 at 98°C for 20 min in a pressure cooker ('Pascal'; Dako Cytomation). The sections were cooled for 10 min and then incubated with either pSurv (1 in 600 dilution or 1.6 µg/ml; 4 o C overnight) or mSurv (1 in 10 dilution or 20 µg/ml; 1h at room temperature). Peroxidase blocking solution (Dako Cytomation) was applied to the slides for 10 min at room temperature to inactivate endogenous peroxidase. The primary antibody was detected by use of a commercial kit (Dako REAL TM Detection System, Dako Cytomation), according to the manufacturer's instructions. Finally, a 3-amino-9ethylcarbazole (AEC) chromogen (Dako Cytomation) was applied to 'visualize' the reaction and the slides were counterstained with hemalum and covered using KP-Tape (Klinipath, Duiven, The Netherlands). IHC for bacterial pellets, normal and lymphoma tissues was performed on arrays, while IHC of pelleted cultured cells was performed on whole sections.
Additionally, an antibody dilution series was tested with formalin-fixed paraffin waxembedded bacterial pellets to define the antibody titre (Keller et al., 2007b) . 
Preincubation of Antibodies
The recombinant GST-survivin fusion protein and the GST protein alone expressed in bacterial cells were purified using gluthatione 4B sepharose beads (Amersham Biosciences), according to the manufacturer's instructions and with minor modifications.
Briefly, induced E. coli cultures (500 ml) were centrifuged and resuspended in lysis buffer (50 mM Tris-HCl, [pH 7.5], 1 % Triton X-100, 150 mM NaCl, 5 mM MgCl 2 , 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride and 10 µg Pepstatin A/ml) and lyzed by sonication. 625 µl sepharose beads were added to the supernatant and incubated for 1 h at 4 °C with mixing by inversion. After washing, the beads were resuspended in 2.1 ml lysis buffer and 2.9 ml 84% glycerol (50% final concentration) and separated into aliquots of 500 µl and stored at -20°C. The purity of the protein and its concentration were determined using SDS-PAGE gels stained with Coomassie blue.
Primary antibodies for survivin were diluted in commercial diluent (Dako REAL TM ) as described above to final concentrations of 1.6 µg/ml (pSurv) and 20 µg/ml (mSurv), respectively. Diluted primary antibodies and GST fusion protein-bound sepharose beads were incubated overnight at 4 °C, at a 10:1 antigen-antibody ratio, and mixed by inversion. Following centrifugation of the bead solution, the preincubated antibody sample supernatant was stored at 4°C and used for IHC instead of the primary antibody where appropriate.
Lymphoma Classification
Lymphomas included in this study were classified using the original tissue sections and according to the revised Kiel classification adapted for the dog as previously described (Fournel-Fleury et al., 2002; Ponce et al., 2004) and by the Revised European American Lymphoma -World Health Organization (REAL-WHO) classification (Valli et al., 2002) .
The cases were immunophenotyped using sections from the original blocks (Keller et al., 2007a) .
Results
Cross-Reactivity of Antibodies with Recombinant Canine Survivin
To establish a reliable method for the immunohistochemical detection of canine survivin, the cross-reactivity of the two anti-human primary antibodies was determined. For this purpose, the entire coding sequence for survivin was cloned from MDCK cells.
Sequencing revealed 100% homology with the previously reported canine survivin reference sequence (GenBank Accession number NM_001003019). In western blotting with lysates of bacteria expressing canine recombinant proteins, both antibodies recognized a band of the expected molecular weight (43 kDa) corresponding to the GST-survivin fusion protein, while the reagents did not label GST alone (Figs. 1A -C) .
Both antibodies labelled formalin-fixed and paraffin wax-embedded bacteria expressing GST-survivin, but not bacteria expressing GST alone or other GST-tagged proteins including canine XIAP, cIAP1, cIAP2, Smac/DIABLO, or Omi/HtrA2, or normal E. coli 
Immunohistochemical Detection of Survivin in Cultured Canine Keratinocytes
After demonstrating cross-reactivity of the antibodies with the canine protein, immunohistochemical detection protocols for survivin were established with cultured canine cells. Both primary antibodies labelled formalin-fixed and paraffin wax-embedded cultured non-neoplastic (Fig. 2) and neoplastic (squamous cell carcinoma) keratinocytes (data not shown). The labelling pattern was identical with both cell types and for each antibody and consisted of a predominantly multifocal cytoplasmic, finely granular signal visible in most of the cells, and a diffuse nuclear finely granular labelling present in approximately 50% of the cells. Use of a polyclonal antibody potentially risks nonspecific labelling due to non-specific reactivity with unrelated antigens. To exclude this possibility, pSurv was preincubated with an excess of canine GST-survivin prior to incubation with consecutive sections of the cells. Preincubation resulted in total loss of signal, suggesting that pSurv labelling is specific (Fig. 2) . The same preincubation procedure was performed with mSurv with similar results. Preincubation of pSurv with GST alone lead only to a slight attenuation of the signal (data not shown). 
Survivin Expression in Normal Tissues
The results of this investigation are summarized in Table 1 with representative images displayed in Fig. 3 . In both fetal and adult cells there was a predominant cytoplasmic expression of survivin. Most positive cell types were labelled by both primary antibodies with the exception of neurons and primary spermatocytes in adult tissues, which were labelled only by pSurv. Biliary ductal cells in adults, which were labelled with pSurv,
were not available for labelling with mSurv because these structures were not Intestine with diffuse cytoplasmic labelling of villus enterocytes and of scattered cells in the lamina propria.
In all sections with preincubated antibody the signal is completely abrogated. Bar, 20 µm. 
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antibody. All positive cell types in fetal tissues were labelled by both antibodies. In general, labelling with mSurv was less intense than with pSurv, except for placental tissue, which was more intensely labelled by the monoclonal antibody. Moreover, labelling with pSurv was generally diffusely homogeneous with superimposed fine granules, while most labelling with mSurv was diffusely homogeneous and labelled granules were rare. Preincubation of the primary antibodies with an excess of GSTsurvivin resulted in complete loss of the signal in most tissues, supporting the notion that the labelling was specific for survivin. In hepatocytes, renal tubular cells and cells of the cutaneous adnexal glands, weak residual labelling persisted after preincubation of pSurv antibody either in all cores (liver, skin) or in a portion of the cores examined (kidney).
The same phenomenon was observed with mSurv for cells of the cutaneous adnexal glands and in macrophages in lymph nodes. This residual reaction may have been due to the expression of unrelated cross-reacting antigens, incomplete depletion of specific antibodies during the preincubation step or the presence of antibodies not specific for survivin.
In all lymphoid tissues included in the array, the majority of lymphocytes were unlabelled, while other cells, tentatively identified as plasma cells and cells of the reticuloendothelial system, showed cytoplasmic labelling. This was confirmed by labelling whole sections of two non-neoplastic canine lymph nodes. In addition, examination of the whole sections revealed very faint nuclear staining of lymphocytes in the centre of some follicle, a finding that was not noted in the arrays due to the limited amount of tissue captured using this technique.
Survivin Expression in Canine Lymphoma
Representative cores containing sufficient amounts of tumour tissue were available for 83 of 95 tumours in the arrays labelled with pSurv and 82 of 95 tumours labelled with mSurv (Table 2 ). In this analysis the most frequent tumour subtypes for each immunophenotype were reported separately and infrequent subtypes and cases that could not be classified were grouped together (other subtypes/not classifiable).
Examples of signals detected with the two antibodies are shown in Fig. 4 . pSurv labelled a high proportion of neoplastic cells in all tumours. The pattern of pSurv labelling was similar to that described for normal non-lymphoid tissues. In general, the percentage of labelled tumour cells and the signal intensity were lower with mSurv.
Nevertheless, mSurv labelled more than 5% of cells in 66 of 82 tumours and more than 40% of cells in 51 of 82 tumours. The labelling pattern for mSurv was predominantly cytoplasmic and diffuse. In all lymphoma tissues, labelling by both antibodies was completely lost following preincubation with survivin-GST. 
Discussion
The present study has examined immunohistochemically the expression of survivin in normal canine tissues and samples of lymphoma. Reports of the expression of this protein in normal adult tissue vary (Andersen et al., 2007; Lechler et al., 2007; Altieri, 2008) . The results of the present study indicate that cytoplasmic expression of survivin is widespread in normal fetal and adult canine tissues and that it is nearly ubiquitous across canine lymphoma subtypes. In tumour cells, cytoplasmic expression of survivin has been suggested to contribute to tumorigenesis through its anti-apoptotic function (Stauber et al., 2007) .
The analysis of canine survivin expression was optimized by screening two commercially available human anti-survivin antibodies against recombinant canine survivin by a variety of methodologies. IHC of paraffin wax-embedded bacteria allows exclusion of non-specific reactions with related proteins once the corresponding cDNAs are available. The majority of immunohistochemical studies on human tissues report use of polyclonal antibodies for detection of survivin, and these are considered to be more sensitive than monoclonal antibodies (Grossman et al., 1999; Ding et al., 2006; Vischioni et al., 2007) . The polyclonal antibody used in the present study has been used previously to label survivin in human specimens (Martinez et al., 2004; Schlette et al., 2004; Ding et al., 2006; Piras et al., 2007; Vischioni et al., 2007) as well as in canine mastocytoma, urinary bladder transitional cell carcinoma and lymphoma (Scase et al., 2006; Rebhun et al., 2008; Velando Rankin et al., 2008) . In two of the latter studies (Scase et al., 2006; Rebhun et al., 2008) , antibody specificity was confirmed by western blot analysis. However, the quality of polyclonal antibodies may vary significantly between different batches and therefore it is advisable to test such antibodies whenever 28 possible before use (Keller et al., 2007b) . While most previous studies were based on the use of a single antibody, the present work confirmed labelling results obtained with the polyclonal antibody by application of the monoclonal antibody mSurv. In general, there was high overall agreement in labeling by these two reagents with differences limited to a weaker signal intensity with mSurv. Since the range of organs showing signals and the reaction pattern were similar with both antibodies, the differences observed likely reflect the higher sensitivity of the polyclonal reagent. Similar findings have recently emerged in a detailed comparison of the labeling of human non-small cell lung carcinomas by the same two antibodies (Vischioni et al., 2007) . In that study both antibodies recognized both cytoplasmic and nuclear full length survivin as well as the alternatively spliced forms ΔEx3 and 2B ectopically expressed in a Human Breast adenocarcinoma cell line (MCF-7) cells. A possible explanation for rare discrepancies in labeling of certain cell types observed in the present study, including neurons in the brain and primary spermatocytes, may reside in the differential recognition of further alternatively spliced survivin isoforms or could derive from non-specific reactions. The latter were at least partially excluded by preincubation of the primary antibody with recombinant canine survivin as a negative control. Overall, it would appear that pSurv is a reliable and sensitive tool for the detection of survivin in dog tissues.
These antibodies identified widespread and predominantly cytoplasmic expression of survivin in normal canine fetal tissues as has been described for man and mouse (Ambrosini et al., 1997; Adida et al., 1998) . In contrast, it appears that survivin expression is more widespread in normal adult canine tissues than previously reported.
The finding of survivin expression in epithelia of the placenta, gastrointestinal tract and skin are in agreement with multiple immunohistochemical studies of adult human and 29 rodent tissues (Chiodino et al., 1999; Gianani et al., 2001; Ding et al., 2006; Lechler et al., 2007; Piras et al., 2007) and with expression data available from a publicly accessible repository (http://www.proteinatlas.org/). Positive expression in several further organs including testis, kidney, liver and brain ( Kobayashi et al., 1999; Altura et al., 2003; Moon and Tarnawski, 2003; Lechler et al., 2007) is supported by at least one previous study with human tissues and by data from the protein atlas. One study in particular has demonstrated, with different methods, high survivin levels in the adult renal proximal tubules (Lechler et al., 2007 (Fukuda and Pelus, 2006) were not included in the present study but these tissues from dogs might also express survivin. In the present study, a more extensive identification of cell types was not possible in the tissue microarrays due to the limited amount of tissue examined and the limited number of tissues included.
Furthermore, the small number of individuals studied precludes assessment of individual variations. However, the data point to widespread expression of survivin in normal adult canine tissues. A more detailed study is warranted, particularly considering the fact that therapies targeting this molecule are currently under investigation in man and are not devoid of side effects (Altieri, 2008) .
Previous reports indicate that survivin is frequently expressed in most cancer types (Andersen et al., 2007; Altieri, 2008) . The findings of the present study suggest that most, if not all, canine lymphomas express survivin and that this molecule might have a role in the genesis or maintenance of these tumours. While pSurv consistently labelled most tumour cells in the majority of the cases analyzed, mSurv labelled fewer cells in a substantial number of tumours, suggesting differences in the level of expression between lymphomas. In a recent report, a negative prognostic significance was ascribed to high levels of survivin expression assessed immunohistochemically in samples of canine B-cell lymphoma (Rebhun et al., 2008) . In that study, survivin was detected in all tumour samples investigated, which is in accordance with our data based on a larger sample size. Those authors did not report the relative extent of nuclear and cytoplasmic labelling, while in the present investigation cytoplasmic survivin appeared to be predominant. In man, survivin is immunohistochemically detected in high grade rather than in low grade lymphomas, which are considered negative (Ambrosini et al., 1997; Tracey et al., 2005) . In diffuse large B-cell lymphoma, survivin expression, detected by IHC, was reported in 43 -80% of cases either in the nucleus (WatanukiMiyauchi et al., 2005; Liu et al., 2007) , in the cytoplasm (Adida et al., 2000; Ambrosini et al., 1997) or without mention of subcellular localization (Tracey et al., 2005) . In mantle cell lymphoma, another subtype of B-cell lymphoma, survivin expression was reported to be rare (Tracey et al., 2005) , while another report described mean expression of 10 -30% of tumour cells with dominant nuclear labelling (Martinez et al., 2004) . Importantly, this latter study, in which pSurv was used, confirmed subcellular localization by western blotting of lysates of tumour cell lines and of tumour cells isolated from patients and subjected to subcellular fractionation. Another group, using the same antibody, identified cytoplasmic survivin expression in 55% of anaplastic large-cell lymphomas (a subtype of lymphoma mostly comprising T-cells) and confirmed the subcellular localization in cell lines (Schlette et al., 2004) . In contrast to these studies in man, both the present investigation and a previous study point to widespread expression of survivin across most subtypes of canine lymphoma (Rebhun et al., 2008) .
In conclusion, by application of a combination of two different antibodies against survivin and screening of arrays of normal tissue, the present study has shown widespread cytoplasmic survivin expression in normal adult canine tissues. These observations should be taken into account when developing therapies targeting this molecule for the management of neoplastic disease.
